ArticleNeoplasia (New York, N.Y.)2011

Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.

Urban Emmenegger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.